MYOS - MYOS RENS Technology Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

MYOS RENS Technology Inc.

45 Horsehill Road
Suite 106
Cedar Knolls, NJ 07927
United States

IndustryDrugs - Generic
Full Time Employees9

Key Executives

Dr. Robert Joseph Hariri M.D., Ph.D.Exec. Chairman and Chairman of the Scientific Advisory Board10.31kN/A58
Mr. Joseph MannelloCEO & Director98.68kN/A59
Mr. Ren RenGlobal Chairman10.31kN/A55
Mr. Joseph DiPietroControllerN/AN/AN/A
Mr. Magshoud DarianiChief Technology OfficerN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


MYOS RENS Technology Inc., a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity. Its products include Re Muscle Health products, a direct-to-consumer portfolio of muscle health bars, meal replacement shakes, and daily supplement powders; and Qurr line of products comprising flavored puddings, powders, and shakes. The company sells its Re Muscle Health products through e-commerce Websites; and Qurr line of products through convenient direct online ordering without a prescription. The company was formerly known as MYOS Corporation and changed its name to MYOS RENS Technology Inc. in March 2016. MYOS RENS Technology Inc. was founded in 2007 and is based in Cedar Knolls, New Jersey.

Corporate Governance

MYOS RENS Technology Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.